alexa
Reach Us +1 218 451 2974
Primary Prevention of Thyroid Associated Ophthalmopathy by Pentoxifylline | OMICS International | Abstract
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Primary Prevention of Thyroid Associated Ophthalmopathy by Pentoxifylline

Balázs Cs1* and Korányi K2

1Teaching Hospital of St. John of God in Budapest, Hungary

2National Institute of Neurosurgery, Budapest, Hungary

*Corresponding Author:
Balázs Cs MD. PhD. DSc.
Department of Medicine & Endocrinology
Teaching Hospital of St. John of God in Budapest
Frankel l. Str. H-1027 Budapest, Hungary
E-mail: [email protected]

Received November 03, 2011; Accepted December 09, 2011; Published December 23, 2011

Citation: Balázs Cs, Korányi K (2011) Primary Prevention of Thyroid Associated Ophthalmopathy by Pentoxifylline. J Addict Res Ther 2:118. doi:10.4172/2155-6105.1000118

Copyright: © 2011 Balázs Cs, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Prospective controlled study was designed for comparing the influence of methimazole (MMI) alone (control group) and MMI+ pentoxifylline (PTX) with respect to grades of thyroid associated orbitopathy (TAO). Control group of patients consisted of 112 patients with hyperthyroidism (mean aged 44.0+/-12.4 yr, 83 female and 29 male). PTX treated group of 112 (mean aged 47.7 +/-10.2 yr, 83 female and 29 male) hyperthyroid patients were treated with MMI+ PTX. At the onset of study there was no remarkable differences between control and PTX treated groups. After six and twelve month observation period the manifestation of TAO with moderate and severe forms were significantly lower in PTX treated patients. Various risk factors were analyzed in both groups. Smoking by itself without genetic factors greatly increased the risk of TAO (OR: 7.1: CI 95% 9.3-5.4). If the smoking habit was associated genetic background, the manifestation of TAO significantly increased (OR: 9.2 CI 95%, 12.1 to 6.9, p< 0.0001). PTX therapy had a beneficial preventive effect on manifestation of eye symptoms and decreased the number of patients both in smokers with and without genetic susceptibility (OR: 2.62 CI 95%, 1.5-3.7, p

Keywords

Recommended Conferences
Share This Page
Top